In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Santhera Pharmaceuticals

http://www.santhera.com/

Latest From Santhera Pharmaceuticals

Tech Transfer Roundup: Santhera Exits Congenital Muscular Dystrophy Pact To Focus On DMD

Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.

Tech Transfer Round-Up Deals

Gaming Industry Entrepreneur Backs Ethris To Be Germany’s Next mRNA Pioneer

An online gaming entrepreneur is injecting new cash and strategic thinking into biotech Ethris – with the goal of making it a ‘gamechanger’ in inhaleable mRNA.

Companies Commercial

Santhera's Transformation Should Turn Investors' Heads

The Swiss biotech had a tough time after the failure of idebenone for Duchenne muscular dystrophy, but CEO Dario Eklund tells Scrip that with a new soon-to-be submitted compound, vamorolone, it has an effective and much safer alternative to steroids for the treatment of the progressive muscle degeneration genetic disorder.

Rare Diseases Business Strategies

Asia Deal Watch: Hanmi Licenses Greater China Rights To Dry AMD Injectable To AffaMed

Plus deals involving GC Cell/Rivaara Immune, Sperogenix/Santhera, EOFlow/Zihipp, Grand/ITM, Tasly/Sutro, LegoChem/Iksuda, Nuance/Aerogen, Frontier/AffiRiS and Piramal/Yapan.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Oy Juvantia Pharma Ltd
UsernamePublicRestriction

Register